Merck Keytruda, Chemotherapy combo meets endpoint for first-line treatment of Breast Cancer Medical Dialogues Bureau18 Feb 2020 4:45 AM GMTNew Delhi: Merck known as MSD outside the United States and Canada, recently announced that the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUD...
Novartis cancer therapy MET inhibitor capmatinib granted USFDA priority review Medical Dialogues Bureau13 Feb 2020 4:15 AM GMTCapmatinib (INC280) is an investigational, oral, potent and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the...
